This Point-Counterpoint is the second of 2 articles on the topic of using randomized controlled trials to study integrative cancer therapies. The first, in the previous issue, explored questions on the validityand wisdom-of proceeding with randomized trials on the great variety of therapies that make up integrative cancer care at this time. 1 In discussing the able responses to that article, an important point was made with regard to randomized studies: for many types of integrative therapies, studies with randomized trials are actually premature. Early-stage phase I-/phase IItype trials are critical precursors to randomized studies of any therapy. Without proper preliminary trials, the design of randomized studies may be inadequate, and the effectiveness of therapies may be missed simply because of defects in experimental design. Such preliminary trials are lacking for many of the therapeutic modes used in integrative care. Thus, before we proceed with randomized trials for many therapies (and for many whole systems of integrative care), it will be necessary to complete some of the earlier stage trials so that we have the data needed to design randomized studies that will truly be able to answer the questions we wish to ask.
Nevertheless, there are some therapeutic elements, as well as herbs and supplements, that may indeed be ready for randomized trials. Many of these comprise the individual complementary therapies that play roles in multidisciplinary integrative care. Examples of such therapies include massage, fish oil, art therapy, and others for which preliminary trials have indeed been done. It is the purpose of the present Point-Counterpoint to explore more deeply some of the practical questions that arise in the implementation of randomized trials in integrative cancer care. While a number of these questions are probably wellunderstood by investigators already involved in inte-grative therapy research, they are questions that may plague those who are just starting out in this area. It is our hope that new investigators, and, especially, complementary and alternative medicine (CAM) practitioners who may be contemplating becoming involved in randomized trials, will benefit from the questions explored in this article.
We have, again, a distinguished panel of respondents to these questions, whose answers explore topics ranging from the basic ethics of clinical research to how best to make sure CAM practitioners feel comfortable as part of a research team. Drs Andrea Cohen and Adrian Dobs generously rejoin us after contributing to the first Point-Counterpoint in this series. Dr Dean Ornish, who has been using randomized trials to investigate the impacts of integrative systems of care in the cardiac setting for well over a decade, shares with us some of the elements that went into the design of his present trial with a diet and lifestyle modification approach to early-stage prostate cancer. Finally, Dr Debu Tripathy, a member of the Advisory Board of this journal, shares insightful perspectives on both trial design and practical implementation of cancer studies from his career in clinical cancer research, as well as his innovative research in the application of Tibetan traditional medicine in cancer care.
Andrea J. Cohen, MD, FRCPC, is an associate professor of medicine at the University of Colorado Health Sciences Center and the director of the Complementary and Alternative Medicine Research Program at the University of Colorado Cancer Center. Her laboratory conducts state-of-the-art clinical, translational, and basic research. Dr Cohen has conducted traditional molecular cancer research including topics in lung cancer on peptides, peptidases, endothelin autocrine loop, and methylation. Dr Cohen's CAM interests include Indian and Chinese medicine, as well as mind-body medicine. She is the principal investigator (PI) on several CAM randomized trials, including the clinical and biological effects of guided imagery for lymphoma and leukemia in bone marrow transplant patients and acupuncture for the side effects of chemotherapy in breast cancer patients. In addition, her lab group is performing preclinical work in homeopathy and natural products. Dr Cohen is a pulmonologist and internist; in addition, she is board certified in holistic medicine.
Adrian Debu Tripathy, MD, is a professor of medicine and director of the Komen/UT Southwestern Breast Cancer Research Program at the University of Texas Southwestern Medical Center in Dallas. A graduate of Duke University School of Medicine, Dr Tripathy completed his internship and residency at the Duke University Medical Center. Following a clinical fellowship in hematology and oncology, he completed a postdoctoral fellowship at the Cancer Research Institute, University of California, San Francisco. He maintains a university-based oncology clinical practice primarily in breast cancer and serves as PI on several regional and national clinical trials as well as laboratory-based projects. Dr Tripathy has conducted laboratory research on tyrosine kinase signal transduction and breast cancer. His clinical research interests currently focus on both standard and innovative approaches to breast cancer treatment, including new hormonal and growth factor therapies as well as preclinical and clinical studies on botanical agents. He is also conducting correlative studies aimed at defining cancer gene and protein profiles that correlate with response to conventional and novel therapeutics.
Question 1.

There are already several models of authentic integrative cancer therapy that have been implemented in community and university settings. While they are similar in their overall methodology, they can be quite different in specific details. In a setting of limited financial resources, how could we select which of these integrative models to study (eg, whole systems of clinical care versus particular applications such as acupuncture for pain management)?
Cohen: With limited financial resources, one way to select an integrative treatment model would be to use outcome data to determine whether the integrative protocol seems effective in reducing either morbidity or mortality, or both; next, you would want to know whether it is practical, affordable, and accepted by patients. Another way to select the model is to use programs with individual therapies or modalities that have already demonstrated efficacy in both preclinical and clinical studies; inclusion of these therapies within the overall treatment approach might suggest grounds for postulating efficacy of the overall treatment model. Committees of integrative experts could help triage the different integrative programs. Finally, initial pilot clinical trials can be performed to obtain preliminary information that could provide directives for larger trials. Dobs: The scientific method involves trying to control as many factors as possible within an experimental framework. A single clinical study can often set the stage for more extensive forms of research involving a particular CAM or integrative treatment approach. Ideally, one would choose an intervention or modality and then establish a control group (ie, a placebo or some kind of comparative group); one could then measure the results of the new CAM procedure against those of the control group. This straightforward scientific approach is being used within CAM research today: comparing, for example, a new acupuncture approach to sham acupuncture, or comparing a dietary supplement to an established pharmaceutical agent. The criticism of this standard research practice is that, in real life, one doesn't just change one variable. In real life, multiple changes take place, and whole systems of medical care are used rather than a single agent or modality. We may want to heed the lessons of non-CAM experiments in which a more holistic approach was adopted. In these studies-most of which involved diabetes and cardiovascular disease, rather than cancer-multiple interventions were implemented at one time. Many of these interventions have taken the form of broad-based lifestyle interventions. With diabetes, for example, not only were drugs such as insulin used, but exercise, weight loss, dietary modification, and cessation of smoking were also used. The same approach can be used with CAM therapies for cancer, in which multiple interventions are used simultaneously, as opposed to just one intervention.
The problem with using this more holistic approach is that multiple interventions imply a more complicated study design. It requires more patients and tends to be much more expensive. The bottom line is that, in most cases, it is going to be much easier for investigators to study a single intervention than to adopt the more holistic approach that is intrinsic to any authentic study of integrative medicine. Ornish: There is some value to studying whole systems of care versus specific modalities, such as Chinese herbs or acupuncture. Well-designed studies of whole systems of care will yield results that are more relevant to the real-life situation most patients face. In our studies, we have looked at diet, meditation, yoga, aerobic exercise, and support groups all at the same time. In general, compared to studying a single diet or lifestyle factor, the impact of such a multidimensional intervention likely will be greater, and therefore the number of patients needed to detect statistically significant differences can be smaller, which in turn helps contain the cost of the study.
You can also argue that if the interventions themselves are all relatively innocuous, as in the case with most lifestyle interventions, then no phase I trial testing is needed, as would be the case with more invasive or toxic interventions. When you're changing several factors at the same time, there is often synergy from both the adherence standpoint and therapeutic standpoints. For example, many people have trouble changing their diet if they don't also find ways to manage stress better. This is particularly true if they are in a stressful job or facing a stressful medical situation. This is one of many examples of how an integrated approach, as in the case of systematic lifestyle changes, will tend to yield more powerful results than one would find with single-agent or single-modality approaches.
The idea that you're changing only one independent variable and measuring one dependent variable is often a myth. A person may think they're doing this when they design a study. In actual practice, however, when you place someone on an exercise program, you're often changing other factors at the same time. Let's say you're investigating the effects of exercise and its effect on secondary prevention of prostate cancer. You devise a study whereby you randomly assign one group to exercise and the other group to no exercise. On paper, it appears that you're only working with one independent variable. In actual practice, however, when you place people on an exercise program, you're not just getting them to do exercise; you're actually affecting other factors that may confound the interpretation of your results. For example, people often exercise with other people, and there's increasing evidence that social support can augment cancer control. You're also affording a sense of meaning by participating in a study, and this sense of meaning can help counteract purposelessness, nihilism, and factors associated with depression, which is extremely common among advanced-stage cancer patients. My preferred approach is to see if we can get a benefit, then use multiple regression analyses or large-scale studies to try to sort out the relative contribution of each component. Even if you're able to control all variables except one, there's an assumption that all people respond in the same way. In fact, they don't. For someone who's under a lot of stress, the stress management component may be more important, whereas for someone who doesn't have much stress but has a history of bad eating habits, the diet may be more important. But when you're looking at a randomized trial, you're just looking at average changes, without recognizing that the impact of diet alone, for example, may be quite substantial in some individuals. You can't sort out those individual effects very easily when you're doing a randomized trial of a whole-systems approach. We don't know the relative contributions of the different components within the system, nor do we know which patients will benefit most from the intervention. At worst, if the stress management isn't as important for a patient as the diet, the worst that can be said is that the patient is better at managing stress than she or he is at attending to her dietary needs.
In the end, we simply need to accept the interpretation that, taken as a whole, a whole-system-of-care intervention produces certain outcomes. If multiple components within the intervention have biological plausibility or at least evidence of preclinical effectivness, then the whole-system approach may be worth studying.
Tripathy:
The challenge is how to decide which approach is best to study and how best to study that approach. If you compare one practitioner of an integrative approach to another practitioner's approach, you will often see substantial differences, and the overall intervention is very complex from a research standpoint. It's important to put your best foot forward and choose which approaches you are going to study, and there are several criteria you could use. The first criterion is that the approach in mind is based on some biological rationale that you can point to that suggests efficacy. Perhaps there are several compounds known to have a biological effect in laboratory studies. This is not an absolute prerequisite, of course, but it is helpful.
Another criterion is a long history of use. Many of the traditional herbs or plant-based diets, for example, have a long track record of use in terms of managing chronic diseases. In many cases, CAM practitioners who have used the particular herb or dietary approach have established a baseline experience on which some preliminary claims or expectations can be based. They have assembled some cases that suggest a benefit; a clinical precedent has been set. This adds some amount of credibility. Some of the models of traditional Chinese medicine (TCM) are helpful in this regard because we have ancient texts on the practice and many thousands of TCM practitioners working worldwide continually documenting their findings.
The final criterion is that it is feasible, applicable, and reproducible. It should be easy to use, and there should not be a great deal of variation in how it is administered. If it is eventually going to be extended to a multicenter study, we have to ask whether it is reproducible in a clinical practice, because ultimately, large-scale clinical trials are likely going to be necessary. These are the criteria I would use to determine which interventions or integrative approaches are best to study. You would of course first conduct a pilot study to determine feasibility and confirm its safety. You would then do a much larger study, ideally a randomized trial. How you handle variability and individualization of treatment is another issue.
Question 2.
A crucial aspect of experimental design is selection of a population in which to explore hypotheses. Different cancers may respond differently to integrative therapies. How could we select which cancers would be most practical and most relevant to study?
Cohen: We may be able to get an idea of efficacy of natural products and energy therapies by screening for cell growth and death in the wet laboratory using cell cultures and animal models. The literature can be reviewed for previous studies on integrative therapies or on components of those therapies; a great deal of preliminary, supportive information can be assembled in this manner.
In addition, CAM practitioners with extensive experience in cancer care can be interviewed about their experience with integrative therapies with regard to specific cancer types. Data could be collected on outcomes from existing integrative treatment regimens both in the United States and internationally. In countries outside the United States, data may be obtained on CAM therapies such as TCM or Ayurveda (without Western treatments). This information would enable us to develop hypotheses for future randomized studies. Finally, we can perform pilot phase I and II studies to get an initial idea of efficacy. The stage and etiology of a particular cancer has a strong relationship with morbidity or mortality, and these factors too need to be taken into account. Dobs: Preliminary data are always the starting point for determining whether one disease or another is worth studying and whether the disease may be more amenable to CAM therapy. One may choose to study a chronic disease, such as breast cancer, as opposed to an acute disease such as leukemia. The latter cancer will typically involve less time and therefore less cost. If funding is ample, CAM studies of breast cancer, colon cancer, and other chronic malignancies that have a high incidence and mortality would be worth pursuing. Ornish: Our decision to study prostate cancer is a good example of the process of what investigators go through. When I looked at the data on prostate cancer, it reminded me very much of how it was in 1977 when we began our studies of heart disease. At the time, the animal and epidemiological data had suggested a role for diet, but no one had bothered to do the interventional studies needed to establish a causal relationship. In trying to decide which cancers to study, it's always good to see what evidence is out there already. If you find that something is true for dogs, cats, rodents, and monkeys, it may be true for people as well. Animal data had indicated that prostate tumors grew fairly quickly in male mice fed typical US diets, but when these same mice were placed on lowfat diets, the tumors no longer grew or even shrank in some cases. Epidemiologically, studies in Japan and rural China had shown that the rates of clinically significant prostate cancer were much lower than in the United States, and thus mortality was and still is substantially lower. Nonetheless, when these native-born Asian men move to the United States, their clinical prostate cancer rates become very similar to what you see in this country. Low-fat, plant-based diets are common throughout southeast Asia. Combining the animal data with the epidemiological data provided a fairly compelling argument for trying a low-fat dietary regimen for men with prostate cancer. Moreover, a subgroup of people who have biopsyproven prostate cancer but elected not to be treated (for reasons unrelated to us) provided a unique research opportunity from an experimental design standpoint. These men are older and have a less aggressive form of prostate cancer; therefore, they're more likely to die with the cancer than from it. Many of the conventional treatments for prostate cancer leave younger men impotent, so they feel that it's better not to do the treatments at all due to the subsequent decline in quality of life. Nonetheless, it would be difficult and unethical to conduct a study of this kind in younger men.
We then randomized our patients to receive the comprehensive lifestyle intervention versus usual care. This allowed us to have a nonintervention control group, which you can't do with most forms of cancer. In breast cancer, for example, most women have to be treated, so differences between the intervention and control groups are less pronounced than they would be with an intervention-versus-no-intervention design. Because the control group is receiving treatment in this case, it is difficult to sort out the relative contribution of the interventional components.
Tripathy: The answer to this question depends on the particular focus of your research. Some cancers respond differently to certain interventions. Many cancers have unique symptoms, but some have shared symptoms. The best course initially is to stay as broad as you can, so that you're not restricting yourself. Let's say that you're looking at a symptom management approach, for example, to explore innovative strategies for improving cancer-related fatigue. If this is your experimental goal or research question, you may want to study many different kinds of cancers and be as inclusive as possible. You may say that you're going to take anyone with cancer who says that, on a scale of 1 to 10, their level of fatigue is 5 or greater. Those would be the inclusion criteria, and you would allow people with all kinds of cancer to join. Obviously, if you're studying an approach that is more biologically driven, such as liver metastasis, then you would be interested in any cancer that spreads to the liver. Even here, you will want to start as broadly as possible. The second issue is which populations are most practical and relevant. I would address this the same way a pharmaceutical company would. You have to ask, What is the area of biggest need? What are the cancers for which current therapies are inadequate? What are the cancer-related situations in which quality of life is impaired (chronic nausea, pain, fatigue, etc)? In terms of incurable cancers, the big ones are cancers of the lung, breast, and colon, so clearly there is a big need there.
In some cases, screening technologies and systems have enabled us to pick up cancers at earlier stages. This is particularly true for cancers of the prostate and breast. One might then ask, Do I study early-stage or late-stage breast cancer? When studying early cancer or prevention, people always ask whether it wouldn't be more effective to target the disease then. The answer is of course yes: early treatment is always the most ideal.
Historically, when we find that a drug works in an advanced-stage disease setting, but it works only temporarily and doesn't cure people, that same drug seems to cure people who have early-stage disease; it may prevent recurrence and actually save lives. Nonetheless, we would not have known this without having first done some research in the advanced-stage setting where it had some effectiveness. The reason that many of us focus on the advanced-stage setting is not that we expect to cure people, but that that is where we expect to know what works. If it does seem to have an impact, then we move it to the early stage.
We do not start in early stage if we're trying to develop a drug that, say, may lower the risk of recurrence. To prove that, you end up having to study thousands of patients. You would never want to launch a study of 1000 patients if the intervention under study only has a 10% chance of working. This is why many of the studies of a new intervention begin with the advanced-cancer setting. Even if there's only a partial benefit, even if it temporarily works or shrinks the cancer in, say, half the people for a few months, then the data are compelling enough to then get funding for early-stage cancer.
If you're looking at a single agent such as a mushroom extract or some other botanical agent that has demonstrated some anticancer effectiveness in the laboratory, it's likely to work only in the early-stage cancer. There's no point in trying to test it in advanced cancer. Nonetheless, you're going to have a very hard time convincing someone to fund a multimillion dollar study of these nonpatentable agents in early-stage cancer.
The problem with this thinking is that we may miss things that would never work at all or give us a signal of possible efficacy in the advanced-stage setting. So far, with conventional cancer therapies, that has not been the case. Most of the drugs that are effective in earlystage cancer have all been shown to have some degree of effectiveness in the advanced setting. I don't think there are any drugs now used in early-stage disease or for prevention that have absolutely no impact in the metastatic setting.
Question 3.
There are already reports of patients being unwilling to be assigned to control groups in trials of dietary supplements for cancer prevention. Assuming randomized controlled trials are to be conducted in integrative cancer care, how would you propose to recruit patients for these trials?
Cohen: In this case, investigators simply have to do their best. There are people who will participate in the study in the name of science or for free supplements. There are people who will not offer to participate in the study because they don't believe in CAM, and still others who won't participate because they do not want to be randomly assigned to the control group. Perhaps they have already made up their minds that a supplement has efficacy or is at least worth trying. This results in a skewed recruitment process that may limit the ability to generalize the results of the study. Advertise widely among physicians and in the community in newspapers. You may need multicenter trials to recruit enough patients.
Dobs:
In any research endeavor, the questions posed by the investigators need to be posed as open questions.
There should be no attempt to convince potential participants of a certain theory or to lay out the likely outcomes in ways that may unduly influence or bias the patient's participation. The patient needs to understand from the outset that we don't have the answers and that the purpose of the study is to answer some very real questions. There are no clear-cut expectations of outcome, at least none that are worth sharing with the patient to the point that they may be expecting certain results. We don't know which intervention is really better for the patient. Indeed, there are many examples of studies in which the placebo was better than the actual treatment group. I feel that it may be worth sharing this with patients who are in the process of being recruited. We can use the example of the Women's Health Initiative with estrogen. Originally, women did not want to be randomized to placebo. They wanted only the active estrogen. Lo and behold, it turned out 10 years later that the women assigned to the placebo did better. The same may hold for any CAM intervention. People need to realize that this is the nature of research. We need to find the answers, and the best way to find those answers is if people are willing to participate in a placebo group, which may even turn out to be the better treatment.
Ornish: In the study context I just described, we found it very difficult to recruit patients, because at least 98% of the individuals were either looking for some kind of treatment or had already received treatment. We were looking for a needle in a haystack. But because of the power of the design of having a nonintervention control group, it was worth the time and resources to try to make it happen. It took us 4 years to recruit 90 people. It's not that they weren't interested, it's that they weren't available.
There is no one way to recruit patients for integrative medicine trials; you do it any way you can. Of course, you first want to run the study by the institutional review board (IRB) to make sure it's ethically acceptable. You then want to talk with the medical specialists-for prostate cancer, this would be the urologists-to help them understand the importance of what you're doing, so that they can assist with the recruiting process. We did have to hold out the carrot to these physicians to get them to cooperate.
Tripathy: You're going to find the most success in randomizing patients when the patients believe there is no clear or correct answer. If the patients perceive that one intervention arm is better than the other, it is going to be very hard to agree to randomization. This is especially the case if that particular intervention is readily available, as is the case with dietary supplements. This is a bit like choosing a jury: you want to find someone who's impartial, who's right on the fence, rather than someone who has a fairly strong bias one way or the other. At the same time, logic would say, "Why would you do a randomized trial of a dietary supplement if there's already fairly strong bias among the participants that it works?" If you already have enough evidence that something works, then obviously you shouldn't be doing a randomized trial. In reality, however, the evidence that a dietary supplement or some novel therapy has a well-defined clinical benefit is flimsy at best; otherwise, you wouldn't be doing the study. What you need to do is convince the public at large of this. I'm not just talking about potential subjects but a broad education effort to the general population to inform them about the true nature of clinical research. In the case of dietary supplements, we need to say that there is potential that these agents may help, but there's also potential that they won't help and that you may simply be wasting your money, or worse, that they may even cause some harm, though the latter is unlikely.
You have to convince potential subjects that you are recruiting for your study exactly as is proposed in the submission to the IRB, giving the synopsis of why you're doing the study. You can suggest to potential participants the following: "If you have a strong feeling one way or the other, then this trial is probably not for you. If you think it's a reasonable question to be asking scientifically, then we would like you to be part of this trial." That's how I actually approach my patients very early on. Many people at a particular institution will assume a study has importance because it has shown preclinical promise and has gone through various review boards. But we want to know whether a person feels a very strong preference for one arm versus another; if they do, they should not be in the study.
The onus is on the investigator to present the study in a very clear way, explaining to the reviewers and the general public why it's being done, without evincing any expectation regarding a better outcome for the experimental intervention versus the control intervention. Equipoise is defined as a state of genuine uncertainty on the part of the investigator regarding the comparative therapeutic merits of each arm in a clinical trial. Essentially, it means giving equal weight to both sides of the argument. In the case of dietary supplements, for example, we would say that the supplements may help, but because the public must pay out of pocket for it, it may be an unnecessary or wasteful addition to the patient's treatment plan. There is always a question of whether true equipoise exists. We investigators tend to have our own biases, of course, and we pass those on to our patients. Or the study participants themselves have their own biases, and that's where randomized trials are difficult-where strong biases exist either on the part of the care team or from the participant's viewpoint.
When there's a new drug for cancer, everyone has the same problem. Phase II trials are fairly easy to do; in contrast, phase III randomized trials are extremely tough, because now you're comparing, for example, standard chemotherapy to chemotherapy plus an exciting new antibody that seems to be reasonably safe. In the early phases, when the antibody isn't readily available, you can elicit a great deal of interest in the study. But once the new drug becomes widely available (as is the case with most dietary supplements), it becomes very difficult to enroll anyone at all in a randomized trial if there is a perceived benefit of one arm.
Question 4.
Many patients who seek out integrative care have researched this area on their own and have developed firm ideas about which CAM therapies they would like to have incorporated in their treatment plan. Is it ethical-or even possible-to assign these patients to control groups in a randomized trial, assuming that they could be recruited to such a trial?
Cohen: First of all, patients have the right not to be recruited to the trial. It can sometimes be difficult to recruit patients. Nonetheless, if they clearly show extremely strong preferences for a specific therapy early on in the recruitment process, I would recommend that they not enter the trial. Another option is that you can build into the study a crossover design, or a waiting period as to when they will get the therapy. I am not a fan of crossover design because many therapies may have unsuspected permanent or long-acting effects. It is hard to predict if the crossover trial will have a period or carryover effect (which must be addressed statistically). After several years of hard work, you could unfortunately find that the effect of the intervention lasted longer than the time between arms of the crossover study. Many published studies do not report these statistical studies. Alternatively, we could use the models of psychotherapy studies in which patients obtain the treatment after a waiting period.
Is it ethical? This depends on the situation. Usually, we would say that if clinical equipoise exists for the 2 treatments, then it is ethical to randomize. Equipoise, in my mind, implies uncertainty about the distribution of costs and benefits on the part of the medical profession. In some studies, true equipoise may be unlikely, and randomization may be unethical. In one recent study, belief in clinical equipoise was the key to having potential participants consent to randomization. 2 The study found that subjects who found equipoise acceptable tended to consent to randomization, while those who could not accept it tended to decline participation in the trial. The investigators concluded that helping their patients better understand and accept equipoise could increase their readiness to participate in clinical trials.
In a review paper by Miller and colleagues on CAM and ethics recently published in the Journal of the American Medical Association, the authors concluded that CAM randomized trials with placebo groups were justified provided that stringent criteria for protecting research subjects were protected. 3 Dobs: As to whether it is possible to do this, the answer is of course, yes. There are several ways to assign these kinds of patients to control groups in a randomized trial, assuming that they could be recruited to such a trial in the first place. But the ethics of the study should always have top priority. This is the fundamental reason the IRBs exist in the first place: to ensure that each study stands on ethically sound ground. IRB committees are always cognizant of the ethics of a study, and one would never want to do an unethical study that could hurt the individual patient who is willing to participate. Determining whether a study is ethical is a group decision that should be made in advance of any actual recruitment. It may be entirely ethical to randomly assign patients to the placebo when it becomes clear that the active group is not any better than the placebo. In the case of more advanced cancers for which effective or at least stabilizing treatment exists, however, it would be unethical to randomize to a placebo; instead, a more pragmatic design would be used, comparing a new treatment protocol to an existing or established treatment protocol. Ethical considerations are therefore intrinsic to the study design. Ornish: The issue of getting patients to participate in control groups can be a real problem in this context. It's one of the many reasons conducting randomized trials is such a challenge. You have to tell people there's a 50/50 chance they'll be assigned to the experimental intervention, and then they know they're going to be tested even if they don't get the intervention. Now, if it's a matter of randomizing to either a drug or a placebo, you don't have to worry very much about crossover because, in most cases, nobody knows what group they're in (except in the case of chemotherapy drugs, in which case placebos don't usually work). With integrative medicine, of course, it's obvious who's in the experimental group. If the people are randomly assigned to the control group, but they understand the gist of the study and know what the overall intervention is, then they may want to do some parts of the intervention. This will dilute the differences between the 2 groups, so that even if there is a therapeutic benefit, you won't be able to detect it. Several modifications of randomization have been recently explored. For example, Dr Marvin Zelen at the Harvard School of Public Health has pioneered a randomized consent design in which you randomize people before you contact them and then you don't have to tell them in detail what the intervention is. 4 Within the Zelen design for a randomized trial, patients are randomized to 2 groups. Those in the first group receive standard treatment; this is the control intervention. Patients randomized to the second group are asked if they will accept the experimental intervention. Those who decline receive the best standard treatment, while only those who accept are given the new intervention. In the statistical analysis of the study's findings, all those in the second group, regardless of which intervention they received, are compared with those in the first group. Enrolling a large number of patients at the outset enables you to compensate statistically for attrition due to having patients in the second group refuse participation in the experimental group.
The Zelen design method has the advantage that, before providing consent, a patient will know whether an experimental treatment is to be used, and this is likely to result in better adherence. You may lose some of the power of the classical randomized controlled trial design because there's always the potential that the reasons for refusal in one group may differ from those of another, but there are ways to compensate for that to make sure that the groups are comparable at baseline. This method tends to reduce known sources of bias and cross-contamination of interventions. Tripathy: This goes back to the issue of equipoise. You have to have a study that presents both arms in a balanced way. If you have a clinical study whereby the evidence is overwhelmingly in favor of one intervention versus another, then you probably should not be doing a randomized trial. Or you should do a study that has built-in safety end points, so that if you're seeing an effect early on, you would be able to appraise all subjects, even the ones already enrolled, about the progress of the trial. When you go to a clinic that provides integrative care, those are precisely the settings in which you're going to have trouble randomizing patients.
When I was at the University of California at San Francisco (UCSF), we used to attract patients who had an interest in this area. At one point, we elected to study an herbal combination to alleviate chemotherapy side effects in a randomized design. Only about 1 in every 10 eligible patients consented to participate. In contrast, if we had taken this same study to a place where patients were coming to receive chemotherapy and had no idea about integrative therapy or herbal therapy, and they were presented with the study concept, you're likely to have far greater success in recruiting these types of patients for a randomized trial. The experimental therapy is likely to be foreign to these patients-they did not seek it out-but it makes sense to them or sounds interesting.
The bottom line is that it's always going to be difficult to randomize patients when they're coming to an integrative medicine center for integrative care. After all, this is why they're coming: to receive the integrative treatment. If you go to another treatment center that does not routinely or publicly provide integrative care, you're going to have more success in recruiting for a randomized trial on integrative care. I think that the centers that do integrative care should be doing the phase I and phase II pilot studies. If the phase II studies indicate promise, then the large randomized phase III studies should be carried out at centers where integrative care is not typically offered, so that the patients are not going to expect to receive such care and therefore are less likely to be biased.
Question 5.
Assuming that the recruitment issues have been adequately addressed, what types of intervention would be appropriate for control groups to receive in a randomized trial of integrative cancer care? Placebo supplements are not problematic, and there has been substantial work in the use of sham acupuncture points. But for a trial of a full integrative care regimen, what might be an appropriate control condition? Would "usual" or "standard" care suffice? Or would it be necessary or desirable to have a "sham" integrative care group? If you feel that a "sham" control would be appropriate, what types of interventions would be suitable for it?
Cohen: I would first do a pilot study with a usual care group to determine whether the integrative therapy is indeed effective and work out the possible problems in the study. In some cases, it may be impractical to implement a sham arm. If the pilot program is effective, sham interventions could include placebo pills for vitamins, natural products, and homeopathy; sham acupuncture; and sham energy work (ie, Reiki, distant healing) by a nonhealer. You could also theoretically perform a study with randomization to multiple groups in which each group had an additional therapy added in a stepwise fashion. This study would require very large groups of patients and may not be practical. Dobs: This a very broad question, because the answer will likely vary depending on the disease situation. In some cases, usual or standard care will suffice as a comparison for, say, an integrative cancer treatment approach. Ideally, however, any kind of intervention should not only have a placebo or sham arm but also a nothing or no-treatment arm. We know that there is a waxing and waning of disease states that may have nothing to do with intervention. We therefore need to have a clear understanding of the natural history of the disease. For some cancers, for example, watchful waiting may be used as the comparison. With prostate cancer, an elevation in prostate-specific antigen (PSA) does not necessarily warrant action, and studies have revealed that doing nothing is often the more sensible course of action for older men with elevated PSA levels. Ornish: There are many factors that go into those kinds of decisions, one of which is the duration of the study. If you're doing a weeklong study, most people in the control group would agree not to do anything, because it's such a short period of time. If you're following people 5 or 10 years, it's very difficult and ethically questionable to ask a control group not to take certain vitamin supplements, herbal remedies, or whatever the modality is, especially if those approaches are of proven value. Much depends on what question you're trying to answer. Sham procedures have their own ethical concerns. As long as people are fully informed of what they may be facing, at least you've addressed those concerns. You're also trying to control for the placebo and power of the belief. The advantages of doing sham acupuncture, for example, help to control for the placebo effects from sticking people with needles and telling them it could be beneficial to them. By analogy, there was a study in which a precursor of today's cardiac bypass surgery, the Vineberg procedure, 5, 6 involving implantation of the internal mammary artery into the left ventricle, was compared with a sham surgery. In the sham surgery, patients were subjected to a similar procedure, but without ligation of the mammary artery. 7 This showed that there was a 50% reduction in angina or chest pain for people who had the sham surgery, simply because there is such a powerful placebo effect when you put someone through surgery, even if the surgery has no medical value.
Frequently, when you're conducting these studies, it becomes a tradeoff between what's ideal and what's practical. In our case, we could not tell the control group not to change their diet. But the dietary modifications we asked the experimental group to make (for both the heart disease and prostate cancer studies) was so intensive that the alterations we expected to see were substantially greater than what would be expected with moderate dietary change. Many people in the control group were already changing their diets in moderate ways, so the differences between the 2 groups would have been minimal or undetectable if the experimental diet had been only slightly modified. We used food frequency questionnaires, weight, and blood cholesterol to assess their adherence, and we used an adherence formula to determine their adherence to each of the 4 components of the program. Despite the arbitrary nature of this formula, we found a remarkable correlation between adherence to each component of the intervention and the changes in PSA as well as in prostate tumor growth in tissue culture. Even with the limitations of selfreported data, to be able to find those kinds of correlations adds to the strength of the intervention. Tripathy: There are 2 parts of the question. One is the ethics of the study. You have to get standard care. If you're studying fatigue, for example, we know there are certain things that can help relieve fatigue. We know, for example, that nutritional support such as specific vitamins that may be depleted by conventional treatments may help alleviate fatigue. Erythropoietin would be helpful in people who are anemic. The standard of care needs to be firmly grounded. You do not want to leave out those interventional components that you know can be helpful or even critical. The other issue is a scientific one: How do you know that your endpoint does not have a placebo effect? Let's say you're doing acupuncture versus no acupuncture. This is where the sham treatment can be very effective, particularly when you have a subjective endpoint such as how much nausea someone is experiencing after a chemotherapy treatment. If you're comparing acupuncture versus no acupuncture, the whole act of coming into a room, sitting down, and talking with the acupuncturist-all of these factors might tend to make them feel better, whereas the actual needling might not be having any effect. This is why the sham has to be as close to the experimental arm, minus the actual factor you're studying. Thus, the true sham treatment could simulate the whole experience of getting acupuncture, including the needle, but not getting that needle in the relevant point. The sham is really important only if the outcome is subjective.
If the endpoint is more objective, as in the case of shrinking a tumor, and you're measuring that with a scan, then it is hard to envision that a placebo effect would be involved. The same goes for regression of metastases or advanced cancers. In these cases, you could do a randomized trial of, say, chemotherapy with an herbal formula versus the same conventional treatment without the herbal formula. Because you are measuring tumor size, survival, or some other hard endpoint, you would not need a sham. Again, however, if you were looking to the herb as a way to mitigate side effects, then you would need a sham because you would need to control for the placebo effect. This would have to be a blinded placebo study to reduce the tendency to elicit biased responses. This is why we really don't see chemotherapy trials that involve placebos other than to measure quality-of-life outcomes.
Question 6.
One of the problems faced in research on integrative care is finding qualified practitioners of CAM therapies and developing them into an integrated clinical or research team. Please describe your experiences with this problem. What advice would you give to other investigators attempting to address this area of research?
Cohen: Fortunately, I have been very successful in the selection of CAM practitioners for my studies. Nonetheless, this is an area in which PIs should be cautious, as the selection of the CAM practitioner can have an important bearing on the outcome of the study. Many qualified CAM practitioners in your local community can be located through referrals from CAM-training institutions. Spend an adequate time selecting your practitioners. They should be formally trained, certified if applicable to their profession, and credentialed at your hospital. You want them to be very experienced, full-time practitioners; you want to avoid the "weekend Reiki master syndrome." Choose CAM practitioners who are supportive of Western medicine and have enough time in their schedule to commit to the study. Also look for experience with academic medicine and record keeping. I prefer working with people who have had a health care career, such as nurses and therapists. Be sure to check the references from the CAM practitioners' patients. In addition, I recommend that one of the members of your team has a course of treatments at their office. This would give you a real-life example of their skills, efficacy, professionalism, bedside manner, and organizational skills. Avoid a practitioner who is disorganized, ungrounded, or too aggressive in their treatment approach. Finally, it is important for any practitioner to engage in clean living. It may also be fruitful to ask around your hospital. Many health care practitioners at your institution may have expertise in CAM practices and might be interested in participating in research.
The PI should take great efforts to incorporate the CAM practitioner into the team and make him or her feel welcome. This includes planning meetings and creating and revising protocols and working manuals. The PI, study coordinator, and head practitioner should routinely audit the CAM team.
Dobs: This is a major problem that will likely continue to hamper progress in the area of CAM therapies and their integration into conventional medicine. We've sought to address this in a number of ways. One is that we're now trying to groom conventionally trained physicians and health care providers by supporting them in obtaining additional training in CAM. Thus, for example, we have a nurse practitioner with conventional training who is now certified in acupuncture. We also have a few MDs who are skilled in the use of acupuncture. Training physicians in various areas of CAM will be an important way to develop the kind of expertise we need to do this kind of work.
A different yet complementary strategy is to take CAM providers in the community and train them in research so that they can directly participate in research studies. That has been a greater challenge to us. Some of the CAM providers simply are not interested in doing clinical research, which requires a good deal of didactic training. Many of these CAM practitioners are not motivated to learn the proper research methodologies or they hold a number of erroneous assumptions about the potential value of doing such research. If the time, desire, or qualifications are not there, it can be extremely difficult to find the right CAM providers to participate in research studies. In general, I feel that most of the attention should be devoted to educating conventional physicians about CAM therapies and training them to do the research within their clinics or treatment centers. If they already work closely with CAM providers, perhaps even under the same roof, then the only real effort needs to be in the area of research and methodological training.
Ornish: It's always hard to find people who are really good at what they do. We've been very fortunate because our work has tended to attract people who are interested in doing this kind of work, particularly both clinicians and researchers who are interested in conducting clinical research. They not only understand the relevance of the research but also have a sincere interest in creating new possibilities for those in need. It's like anything in life: finding people who are right for the job is an iterative process. There's no way to tell in advance who is truly best for the job. My threshold for letting go of people is much lower than it used to be. I used to view having to terminate someone as failure but now simply see it as not a good fit in many cases. This often becomes clear early on. When it does become clear, you have to speak with the person right away. It becomes a process of people selecting themselves out, so that those who are good at this work and have a passion for it remain.
Tripathy: This is a very difficult challenge, getting a good team together. CAM practitioners are typically very busy people. They are working for a living; they are dependent on seeing patients on a consistent basis, and they have to keep up with their field. The amount of free time they have to sit down and write protocols or get trained in research is very limited. So the first answer is that this takes a long time. It took us about 6 years to assemble our team and become productive to the point where we were securing grants and getting publications out. You first need to think about the kinds of people you want on your team. You want to begin with a multidisciplinary array of practitioners, including people from the CAM field who are able to address a particular disease situation. In the case of cancer, you would want a medical or surgical oncologist. You would then want a trained or licensed CAM practitioner. We used an herbalist-acupuncturist who had gone through a certification process and had the proper training. You then want someone as a research coordinator, someone who is fluent with administrative and regulatory issues and how to put together trials. Then you need statistical expertise to help you decide how many people you need on your trial and how to analyze the data, how to build your database. Those are the key components. The next priority will be to get start-up funds to bring in your CAM practitioners to work with your team. You want them to come in and explain what the treatment is like so that you can write it out as a protocol. This may take a year or two. These people will be canceling appointments with patients to meet with you periodically, so they need to be funded. I have found that over a few years, our CAM practitioners have become very adept at writing protocols, so adept, in fact, that the 2 I work with now are writing their own protocols; they've actually started their own company and are now writing their own grants. Any time you are trying to launch an integrated research team with clinicians and investigators, it takes time. This is true in the area of basic science, as I found out when I was working in the area of molecular biology. The CAM practitioners began learning about biostatistics, while the biostatisticians started learning about what the whole reason for individualization of CAM therapies was all about. Everyone learned from each other.
You need to get a solid commitment from someone, whether it's a hospital or medical center for a grant, but you also need funds to keep your research team together. You also need a strategy that conveys a thematic area. You need to know the area you are trying to study and why you are uniquely suited to do it. For example, you may have CAM practitioners who see many cancer patients and frequently deal with chronic symptoms, such as chemotherapy-induced neuropathy. They may have found certain natural agents were effective in reducing neuropathy, and now the key is how to carve out that clinical area and write a focused research protocol for that area. You need to be linked with a team that is experienced in writing grants and obtaining extramural funding. That is not just something that anybody can just sit down and do. Usually what it means is that the team would already be part of a university or link up with the university. There are plenty of private groups that do good research and are successful in getting grants, but you want to have someone who has a good track record in getting philanthropic grants and government grants. The most important thing is to be patient because it can take a long time before the team is productive.
Summary and Discussion
Shortened versions of each of the questions precede discussion sections. Discussant is Keith I. Block.
Question 1.
Choosing Integrative Therapies for Study
Response
Choosing a system to study is the first decision faced by any researcher. In the field of integrative care, a primary question is whether to choose to study a whole integrative system composed of multiple CAM therapies, possibly incorporating a conventional treatment scheme, or to explore the contribution of a single CAM therapy. The researchers contributing to the Point-Counterpoint explore several dimensions of this question. Dr Andrea Cohen mentions the roles of outcome data and data from pilot clinical trials, which are certainly consistent with the usual scientific approach to choosing study models. Practicality, expense, and patient acceptance are interesting preliminary variables that she suggests as ways of selecting study models, in addition to efficacy and safety. Dr Adrian Dobs proposes the model of multidisciplinary treatment of diabetes and cardiovascular diseases as an example of how research in whole-system integrative interventions might be conducted but cautions that complicated study designs, large numbers of patients, and substantial expense might result from the decision to study such models. She concludes that study of single interventions will ultimately be much easier for most investigators.
Dr Dean Ornish takes a somewhat different approach from Dobs. He points out that the impact of a whole-systems approach is likely to be much larger than single interventions, a proposition that can be tested in a single-group pilot study before embarking on an expensive randomized trial by comparing single-group results with what is usually reported in the literature. The magnitude of the differential in the outcome variables between the whole-system intervention and the results seen under usual care is critical in designing further research. This differential enters into the power calculations used to determine numbers of patients that should be in each group in a randomized study. The size of these groups is critical in statistical analysis because if the groups are too small, even a very effective intervention will not turn out to be statistically different from the control condition in the study. When there is a large differential between the experimental treatment and the control or usual care condition, group sizes can be smaller. When the differential is small, the group sizes must be larger. Ornish's key insight is that the whole-system intervention with a large impact on outcome can actually result in a smaller group size needed for the randomized trial. His approach truly argues for the feasibility and necessity of studying whole systems. This contrasts with the situation described by Dobs, in which she envisions multidisciplinary treatments as requiring larger groups and more complicated designs and single interventions as the more feasible and practical alternative.
I suspect that a difference in the points made by Dobs and Ornish stems from other sources of variability in study designs. Ornish's proposition, and the type of work he performs, involves treating the whole system of diet, meditation, yoga, aerobic exercise, and support groups as a single experimental "variable," what is often called the "black box" approach to studying whole systems. The situation that Dobs discusses may involve multiple experimental arms with different combinations of the multidisciplinary treatment, which will certainly involve more complexity and expense. The black box approach is meeting with greater acceptance in the CAM research community and should, I think, prove a viable model for research on entire integrative systems.
Dr Debu Tripathy takes a different approach to the question of choosing systems by outlining other criteria for selection. The first of these is biological ratio-nale. The second, interestingly, is long history of use. Tripathy points to the development of what are, essentially, preliminary data that have been assembled formally or informally by CAM practitioners. In some instances, these are actual cases selected by the practitioner; in other instances, written traditions such as Chinese medicine attest to the benefits of treatment practices. Finally, Tripathy mentions feasibility, easy application, and reproducibility as good criteria for selecting research systems. Individualized treatments are common in CAM approaches to many diseases, which can make them difficult to study, although not impossible, once the rules of individualization are clarified. What is important is that even in an individualized treatment, protocols should be reproducible because of the need to eventually bring them into large-scale trials.
Question 2.
Selection of Disease Condition for Study
Response
Cohen mentions reviewing the state of knowledge among CAM and integrative practitioners on how different cancers react to therapies that may be of interest, while Dobs points out the contrast between choosing a cancer that can be managed as a chronic disease, such as breast cancer, as opposed to a cancer with a more acute course such as leukemia. In this situation, of course, the integrative therapies (especially single therapies) would have more time to work on the chronic than on the acute conditions. Ornish explains the roots of his current research, which employs a sort of "natural experiment" in prostate cancer, working with patients who choose not to receive conventional treatment. This was not a group that decided to go without conventional treatment because they were interested in pursuing alternative cancer treatments, but rather a group that chose to forgo conventional treatment to avoid associated treatment risks. This presently is an option for some early-stage prostate cancer patients. Choosing this group enabled Ornish to ethically use a nonintervention control. This is an unusual condition for cancer research since cancer patients routinely receive conventional treatment as standard-of-care medical practice, and integrative care systems must usually tailor their treatments to patients who are receiving, or have previously received, conventional medical interventions.
Tripathy discusses the strategy of testing new treatments in patients with advanced cancers. This is another setting in which treatments can be tested in smaller numbers of patients, although with potential applicability to larger numbers of patients. In earlystage cancers, a relatively small number of patients are likely to have disease recurrence or progression within the time frame that is practical for studying a new agent or treatment. Thus, the number of patients who would have to be recruited and exposed to the new treatment is quite large. A large percentage of patients with advanced cancer, however, experience tumor growth and disease progression in a relatively short period without undergoing treatment. Studying the effects of a new treatment in these patients typically means determining "response," that is, whether the treatment produces tumor regression or lengthens intervals before recurrence. These variables are not related to cure, but, as Tripathy points out, agents that produce responses in advanced cancer are also effective in earlier stage cancers.
One wonders, of course, whether the use of integrative therapies in advanced cancers is likely to be able to overcome the aggressive course of these cancers. This is a case in which most single integrative therapies would, indeed, face an uphill battle. Multifaceted integrative programs that include nutrition, exercise, supplements, psychosocial dimensions, and innovative modes of conventional treatment administration are more likely to have a substantial impact in the advanced cancer setting. In manuscripts now in preparation at our clinic, we report substantial survival differentials between integrative patients and data recorded in the literature for patients receiving similar conventional treatments alone. Perhaps, then, preliminary work among patients with advanced cancers will be an option for full integrative programs. These programs may then, as Tripathy explains, be investigated for their effectiveness in earlier stage cancers.
Question 3.
Patients Unwilling to Undergo Randomization
Response
Cohen poses the nature of this problem succinctly: there are some patients who won't volunteer for CAM studies because they don't believe in CAM. Then there are others who won't volunteer because they want the supplement or CAM intervention, rather than the control. She brings up a particularly interesting point about the results of the way this fact of life skews recruitment to a particular population-the possibility that the group of patients we are able to actually enroll in our research may be so different from the general public that the generalizability of our studies is affected. This is a problem that is, at this stage of our development, probably insoluble. One hopes that as CAM and integrative therapy, as well as the nature of scientific research, become more widely understood, participation in CAM research will not be restricted to an unusual segment of the population. Of course, as Dobs cogently points out, the same problem faces investigators in conventional research. For years, it was apparently difficult to get women to agree to be randomized to control conditions in studies of estrogen replacement therapy. Now that the results of numerous analyses have shown the dangers of estrogen therapy, it would be difficult, if not unethical, to ask women to be randomized to an estrogen group. The extent to which patients in general understand the fact that a research study is a proposal of doubt, rather than a ringing endorsement of a treatment, is questionable. This may apply particularly to patients in the cancer CAM situation, in which award of research funds sometimes appears to patients to be a certification of efficacy.
Ornish recounts an arduous process of recruiting patients to his study: 4 years of recruitment to obtain 90 patients for the study, finding patients "any way you can." He appropriately mentions the involvement of medical specialists who are critical in referring potential study participants to the researcher. Because many physicians still regard integrative care with suspicion, it may be difficult to make the connections with such specialists. But, particularly for cancers in which effective treatments are genuinely lacking, specialists may be more flexible and cooperate more readily.
Tripathy deals more fully with the question of what patients asked to participate in a clinical trial do and do not understand and the need to communicate clearly to them that if they have a strong bias one way or another about the efficacy of an intervention, the trial is not suitable for them. He also points out that new cancer drugs have the same problems as CAM and integrative interventions. Patients may go to enormous lengths to pursue new cancer drugs in earlystage clinical trials because of the potential hope they offer, with results that may certainly be biased by a strong placebo or expectation effect. For drugs that have already been approved and are widely available, the difficulty of recruitment rises.
Question 4.
Can Patients Who Have Sought out Integrative Care Be Assigned to Control Groups?
Response
Cohen recommends that if patients truly want a particular therapy, they should not attempt to enroll in a randomized trial of that therapy. She also dis-cusses in more detail the concept of equipoise, which represents uncertainty about a treatment protocol on the part of the collective profession. Interestingly, she points out that the uncertainty may not necessarily pertain to the individual doctor administering the treatment, who must, nevertheless, share enough of the collective uncertainty to participate in a trial. Dobs also points out the importance of collective decision making regarding the ethics of research: the basic decision about whether a trial design is ethical is a group effort, made with the oversight of an IRB, which would certainly need to be made aware of any plans to assign patients to control groups who had presented at a treatment center looking for a treatment.
Ornish points out the problem of patients assigned to the control group who want to do parts of the intervention, once they understand the gist of it, diluting differences between groups. He mentions the Zelen method of randomization as one way that has been proposed to overcome problems of this sort, in which prospective subjects are randomly assigned to the experimental or control group before initial contact about the study and only the intervention of the group to which they are assigned is explained to them. The control group thus does not even know that they have been randomized to act as controls, overcoming the possible psychological burden that accompanies knowledge of control status. This is certainly a tempting possibility to the researcher contemplating eventual clinical trials in integrative medicine.
Ornish alludes to some of the problems with this method and ways to overcome them; some recent reviews have discussed this method from ethical and practical viewpoints. 8, 9 Another interesting study interviewed parents who had been conventionally assigned to experimental and control groups in a neonatal trial, who were later presented with information explaining Zelen randomization and asked their opinions about it. 10 About half the parents viewed it negatively, and half positively. The parents who viewed it negatively were more likely to have been assigned to the control group. The authors comment that the control group is exactly the group that Zelen randomization is supposed to protect, but it should also be pointed out that the control group is also the one that would be more manipulated ethically than the experimental group by Zelen randomization, especially in trials of integrative medicine at the present time, in which experimenters may hope, essentially, to manipulate control patients into not taking supplements and other treatments in which public interest is high. It may be comforting to investigators interested in integrative medicine that the Zelen method was invented because of vexing problems in designing trials of conventional medicine! Discussion of Zelen randomization also highlights a basic ethical tension in doing randomized trials: do we want to view experimental subjects as partners in a trial in which we truly don't know the validity of a treatment and in which subjects and experimenters alike form a social unit to investigate the question? Or do we want to manipulate the perceptions of the 2 subject groups so that each feels they are the "special" group selected to preview a new treatment, gaining the possible benefits (if any) of the placebo effect? The Journal of the American Medical Association article by Miller and colleagues mentioned by Cohen adds depth to this discussion by highlighting studies in which there were experimental, placebo, and no-treatment groups, as well as by outlining some of the basic ethical goals in randomized trials that need to be balanced with each other, including the goal of obtaining truly valid scientific data so that good treatment decisions can be made for society as a whole.
Tripathy recounts experiences in attempting to recruit patients attending an integrative clinic at UCSF to participate in a trial of an herbal mixture for chemotherapy side effects. The patients, unsurprisingly, did not respond very positively to recruitment efforts. He points out that patients at a center that gave only conventional chemotherapy would likely have responded better, as long as the trial was explained in a way that made sense to them. He concludes with the suggestion that phase I and phase II trials and pilot studies should be conducted at integrative care centers, while the larger phase III trials should be conducted at centers that do not typically offer integrative care.
While this is a very interesting suggestion, I do see some potential for problems with the model of transplanting complex integrative care regimens to centers that do not usually offer them. It would be difficult to implement a comprehensive integrative regimen at a site with medical staff unfamiliar with and possibly unsupportive of the program. Our experience is that acquiring and training staff members able to effectively provide such care in close collaboration with staff trained in conventional medicine is one of the fundamental issues in obtaining good clinical results with patients. While individual complementary interventions could certainly be provided from conventional centers for phase III trials, I think it will take a substantial effort to set up an integrative care facility within a fully conventional hospital. Some universitybased programs may approach this model. I would add that patients at integrative care centers can and certainly should be recruited to randomized, multicentered trials of single interventions such as herbs, supplements, or physical care techniques that are not part of the specific integrative intervention offered at their center, since in this case the physician introducing the study can truly present it to the patient from a standpoint of equipoise about the study intervention. This allows patients at integrative care centers to participate in randomized trials, increasing the pool of patients available at these trials and offering these patients the benefits (and risks) of research. Cooperation with such efforts as the National Cancer Institute's Community Clinical Oncology Program should be a goal for integrative centers that provide chemotherapy and other conventional treatments.
Question 5.
What Type of Placebo or Sham Intervention Is Suitable for Randomized Studies of Integrative Care Systems?
Response Before a randomized trial of an integrative intervention, Cohen points out, a pilot study should always be carried out to make sure that the intervention works or, perhaps, whether the assessment methods that have been chosen to determine if the intervention works are adequate. Cohen points out that this is the time to work out problems in the study. Such problems would include recruitment difficulties, difficulties with standardizing or communicating the intervention, and problems in study coordination, especially if multiple practitioners are involved, in addition to problems with assessment methods. Dobs makes the very interesting suggestion that a no-treatment control should also be used to account for the effects of waxing and waning of disease conditions, and this certainly makes sense, especially for complex interventions that involve substantial interactions with caregivers. Investigators may want to construct controls for complex interventions that offer fairly complex interactions with control group caregivers to account for the nonspecific effects that caregiver time has on patients. However, the assertion that such complex control conditions are actually reasonable sham procedures as counterparts of integrative therapy has not really been investigated, and they may simply represent another "integrative" treatment that delivers various nonspecific as well as specific effects. A notreatment group certainly makes sense in this case.
Ornish points out some particularly interesting examples of sham procedures, including the dramatic effect of sham surgery employing a modification of the Vineberg procedure, which proved to be as effective as the procedure itself in relieving the pain of angina. The placebo effect of surgery in the double-
Point-Counterpoint
blind trial was remarkable and is one of the pieces of data that is important in the concept of the "meaning response" 11 as a coalescence of various symbolic dimensions of physical healing. More practically, Ornish reports that the diet and lifestyle intervention in his experimental prostate cancer group is so intensive that even the moderate changes made by the patients in the control group did not make enough difference to disrupt the correlation between adherence to the experimental regimen and changes in PSA. This is important news: the ability to demonstrate correlations between lifestyle changes in the experimental regimen and changes of a cancer marker such as PSA truly demonstrates the potential of this treatment model for early-stage prostate cancer to overcome the variability introduced by the control patients' lifestyle changes.
The degree to which this model is applicable in other cancers and cancer stages remains to be demonstrated, however. In virtually every other cancer setting, patients receive highly invasive conventional treatments as standard of care, and Ornish's notreatment control model is thus inapplicable. When studies of integrative care in these cancers are implemented, patients in the control group in most cancers will need to be receiving the same chemotherapy or other treatments as those in the experimental group. The conventional treatments will cause declines in tumor markers, in addition to any that might be caused by intensive lifestyle changes in the experimental group or by variable and moderate lifestyle changes in the control group. Will moderate lifestyle changes made informally by the control group also have a minor impact in the setting of tumor markers declining due to simultaneous conventional treatment administration in both groups? It's a question that will need exploration in preliminary studies. In addition, the Ornish diet does not appear from this description to contain the necessary adaptations for individualizing dietary and other interventions to the shifts in nutritional status that are experienced by chemotherapy patients, which can have a high degree of interpatient variability, further clouding the distinctions between experimental and control groups.
Tripathy discusses the use of objective endpoints such as tumor shrinkage or regression of metastases, typically used in studies of chemotherapy and radiation, noting that it is difficult to envision a placebo effect that would produce such responses (although there are reports of tumors shrinking in response to alternative treatments that are known to be ineffective, such as Krebiozen 12 ). He contrasts these situations with those involving subjective responses, such as quality-of-life studies, asserting that unlike quality-oflife studies, chemotherapy efficacy trials do not usually employ placebos because outcomes such as tumor shrinkage are not likely to be induced by placebo (or meaning) responses. Of course, there is a theoretical argument for using placebos in such trials to account for the natural waxing and waning of disease. It is also the case, however, that it would now be considered unethical to give a cancer patient a placebo rather than an active treatment; thus, new chemotherapy drugs are usually compared to current usual care rather than to placebo. Question 6.
How Does One Find Competent CAM Practitioners to Participate as Caregivers in Clinical Trials?
Response Cohen has had good success in finding such practitioners and gives several practical suggestions, including certification as applicable, prior background of careers in health care, having a team member undergo a course of treatment with the CAM candidate, and avoidance of the "weekend Reiki master syndrome" (which, by the way, appears among physicians as well as among other types of health care professionals, who may take short courses in a CAM subject and become overnight self-appointed experts in the field). She also emphasizes the necessity to incorporate CAM practitioners and make them feel welcome as members of the study team, in addition to auditing their practices. Dobs, on the other hand, has had less positive experiences and advocates using conventionally trained health care practitioners rather than those trained only in CAM disciplines. She has found little success in training CAM providers in research techniques and has encountered resistance to learning research methodologies.
It may be that what Dobs is encountering in her difficulties with CAM practitioners results from commencing CAM studies relatively recently, since Ornish, who has been working in this field for decades, reports that his institute has attracted many people interested in this work. Nonetheless, he also has encountered practitioners who were unable to work productively as members of his team and finds that there is no way to tell in advance which providers will actually fit in with his working environment. At my integrative clinical practice, I have encountered the same phenomenon and have instituted a trial period, with a formal evaluation taking place before offering practitioners long-term positions. I have recognized that it takes time to develop an effective and cohesive staff.
Tripathy offers some excellent insights into the problems that underlie the difficulty with enlisting competent CAM practitioners in research, also warning that it will take a long time to develop an effective team, although he notes that the effort is worthwhile, as CAM practitioners can become effective researchers. He points out the difficulties busy CAM providers have in fitting research into their schedule of patient care. He also mentions that it may take more than a year to work out a research protocol with these practitioners but that in the end, they are quite capable of writing their own research grants, interacting with biostatisticians, and becoming independent researchers. Tripathy also provides a useful outline of all the people who need to make up a research team.
Research on integrative cancer care is a new field and is apparently undergoing growing pains just as any other developing organism does. This Point-Counterpoint, second of 2 on the subject, has surveyed several areas of growing pains, from a variety of perspectives. Some of the overlaps and parallels with research on conventional medications have been curious, such as those with recruitment difficulties. The diversity of viewpoints expressed has also been interesting, particularly in the first Point-Counterpoint on the question of whether randomized trials are suitable ways to study integrative care. As I concluded in the discussion of the first Point-Counterpoint, randomized trials are certainly a reasonable way to study integrative care, and in certain areas, we are quite ready to go ahead with them at this time. However, in other areas, such as the application of full integrative systems, the greater need is for preliminary phase I/IItype studies to develop the information needed to perform such randomized trials correctly. The topics discussed in this second Point-Counterpoint give those interested in participating in research on inte-grative care systems an insight into the difficulties inherent in the process of doing randomized trials in this area, as well as some examples of researchers who are moving ahead with randomized trials.
